Molecular characterization of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

dc.contributor.authorPinyol, Roser
dc.contributor.authorTorrecilla, Sara
dc.contributor.authorWang, Huan
dc.contributor.authorMontironi, Carla
dc.contributor.authorPiqué Gili, Marta
dc.contributor.authorTorres Martín, Miguel
dc.contributor.authorWei-Qiang, Leow
dc.contributor.authorWilloughby, Catherine E.
dc.contributor.authorRamadori, Pierluigi
dc.contributor.authorAndreu Oller, Carmen
dc.contributor.authorTaik, Patricia
dc.contributor.authorLee, Youngmin A.
dc.contributor.authorMoeini, Agrin
dc.contributor.authorPeix, Judit
dc.contributor.authorFaure-Dupuy, Suzanne
dc.contributor.authorRiedl, Tobias
dc.contributor.authorSchuehle, Svenja
dc.contributor.authorOliveira, Claudia P.
dc.contributor.authorAlves, Venancio A.
dc.contributor.authorBoffetta, Paolo
dc.contributor.authorLachenmayer, Anja
dc.contributor.authorRoessler, Sthephanie
dc.contributor.authorMinguez, Beatriz
dc.contributor.authorSchirmacher, Peter
dc.contributor.authorDufour, Jean-François
dc.contributor.authorThung, Swan N.
dc.contributor.authorReeves, Helen L.
dc.contributor.authorCarrilho, Flair J.
dc.contributor.authorChang, Charissa
dc.contributor.authorUzilov, Andrew V.
dc.contributor.authorHeikenwälder, Mathias
dc.contributor.authorSanyal, Arun
dc.contributor.authorFriedman, Scott L.
dc.contributor.authorSia, Daniela
dc.contributor.authorLlovet i Bayer, Josep Maria
dc.date.accessioned2023-06-26T14:48:02Z
dc.date.available2023-06-26T14:48:02Z
dc.date.issued2021-05-13
dc.date.updated2023-06-26T14:48:02Z
dc.description.abstractBackground and aims: Non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) is increasing globally, but its molecular features are not well defined. We aimed to identify unique molecular traits characterising NASH-HCC compared to other HCC aetiologies. Methods: We collected 80 NASH-HCC and 125 NASH samples from 5 institutions. Expression array (n = 53 NASH-HCC; n = 74 NASH) and whole exome sequencing (n = 52 NASH-HCC) data were compared to HCCs of other aetiologies (n = 184). Three NASH-HCC mouse models were analysed by RNA-seq/expression-array (n = 20). Activin A receptor type 2A (ACVR2A) was silenced in HCC cells and proliferation assessed by colorimetric and colony formation assays. Results: Mutational profiling of NASH-HCC tumours revealed TERT promoter (56%), CTNNB1 (28%), TP53 (18%) and ACVR2A (10%) as the most frequently mutated genes. ACVR2A mutation rates were higher in NASH-HCC than in other HCC aetiologies (10% vs. 3%, p <0.05). In vitro, ACVR2A silencing prompted a significant increase in cell proliferation in HCC cells. We identified a novel mutational signature (MutSig-NASH-HCC) significantly associated with NASH-HCC (16% vs. 2% in viral/alcohol-HCC, p = 0.03). Tumour mutational burden was higher in non-cirrhotic than in cirrhotic NASH-HCCs (1.45 vs. 0.94 mutations/megabase; p <0.0017). Compared to other aetiologies of HCC, NASH-HCCs were enriched in bile and fatty acid signalling, oxidative stress and inflammation, and presented a higher fraction of Wnt/TGF-β proliferation subclass tumours (42% vs. 26%, p = 0.01) and a lower prevalence of the CTNNB1 subclass. Compared to other aetiologies, NASH-HCC showed a significantly higher prevalence of an immunosuppressive cancer field. In 3 murine models of NASH-HCC, key features of human NASH-HCC were preserved. Conclusions: NASH-HCCs display unique molecular features including higher rates of ACVR2A mutations and the presence of a newly identified mutational signature. Lay summary: The prevalence of hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH) is increasing globally, but its molecular traits are not well characterised. In this study, we uncovered higher rates of ACVR2A mutations (10%) - a potential tumour suppressor - and the presence of a novel mutational signature that characterises NASH-related HCC.
dc.format.extent34 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec718036
dc.identifier.idimarina9242365
dc.identifier.issn0168-8278
dc.identifier.pmid33992698
dc.identifier.urihttps://hdl.handle.net/2445/199885
dc.language.isoeng
dc.publisherElsevier
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.jhep.2021.04.049
dc.relation.ispartofJournal of Hepatology, 2021, vol. 75, num. 4, p. 865-878
dc.relation.urihttps://doi.org/10.1016/j.jhep.2021.04.049
dc.rightscc-by-nc-nd (c) Elsevier, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationModels animals en la investigació
dc.subject.classificationCàncer de fetge
dc.subject.classificationSíndrome metabòlica
dc.subject.classificationModels moleculars
dc.subject.classificationMutació (Biologia)
dc.subject.classificationObesitat
dc.subject.otherAnimal models in research
dc.subject.otherLiver cancer
dc.subject.otherMetabolic syndrome
dc.subject.otherMolecular models
dc.subject.otherMutation (Biology)
dc.subject.otherObesity
dc.titleMolecular characterization of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
718036.pdf
Mida:
664.46 KB
Format:
Adobe Portable Document Format